# US 2001/0025108 A1 · Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025108 A1
- Document ID: US20010025108A1
- Status: Published application
- Kind: A1
- Application number: 09/849,319
- Filed: 2001-05-04
- Published: 2001-09-27
- Earliest claimed: 1998-11-19
- Assignees: Berlex Laboratories, Inc.
- Inventors: Gary B. Phillips
- Web page: https://patentgrep.com/patent/US20010025108A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 405/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is directed to poly-hydroxylated monocyclic N-heterocyclic derivatives selected from the following formulae: 1 wherein Z1, Z2, R1, R2, R3, R4, R5, R6, and R7 are defined herein. These compounds are useful as anticoagulants.

## Claims

### Claim 1

A compound selected from the group consisting of the following formulae: 17
wherein:
A is —C(R8)= or —N= (where R8 is hydrogen, alkyl or halo);
Z1 is —O—, —N(R9)—, —CH2O— or —S(O)n— (where n is 0 to 2);
Z2 is —O—, —N(R9)—, —OCH2— or —S(O)n— (where n is 0 to 2);
R1 and R4 are each independently hydrogen, halo, alkyl, nitro, —OR9, —C(O)OR9, —C(O)N(R9)R10, —N(R9)R10, —N(R9)C(O)R9, or —N(H)S(O)2R11;
R2is —C(NH)NH2, C(NH)N(H)OR9, —C(NH)N(H)C(O)OR11, —C(NH)N(H)C(O)R9, —C(NH)N(H)S(O)2R11, or C(NH)N(H)C(O)N(H)R9;
R3 is hydrogen, halo, alkyl, haloalkyl, nitro, ureido, guanidino, —OR9, —C(NH)NH2, —C(NH)N(H)OR9, —C(O)N(R9)R10, —R12—C(O)N(R9)R10, —CH(OH)C(O)N(R9)R10, —N(R9)R10, —R12—N(R9)R10, —C(O)OR9, —R12—C(O)OR9, —N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl);
R5 and R6 are independently hydrogen, halo, alkyl, haloalkyl, nitro, N(R9)R10, —C(O)OR9, —C(O)N(R9)R10, —C(O)N(R9)CH2C(O)N(R9)R10, —N(R9)C(O)N(R9)R10, —N(R9)C(O)R10, —N(R9)S(O)2R11, or —N(R9)C(O)N(R9)CH2C(O)N(R9)R10;
R7 is —X—CH2—[C(R13)H]p—C(R13)H2 or —X—C([C(R13)H]pC(R13)H2)2H where:
p is 0 to 5;
X is —O—, —S(O)n—(where n is 0 to 2), or —N(R9);
and each R13 is independently —[C(OR9)H]m—CH2—OR9 (where m is 1 to 4), —[CH2)n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n-N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n-N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
or R7 is selected from the group consisting of the following formulae: 18
where
q is 0to 4;
p is 0to 5;
each R13 is independently —[C(OR9)H]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —(CH2)nOC(O)R9, —[CH2]nSC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R 14 is —X—[CH2]r— or —X—CH2—[C(R13)H]r—, where:
each r is independently 0 to 5, and
each X is —O—, —S(O)n—(where n is 0 to 2), or —N(R9)—; and
each R13 is independently —[CH(OR9)]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); and
each R12 is independently an alkylene or alkylidene chain;
as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 selected from formula (I): 19
as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2 wherein:
A is —N=;
Z1 is —O—, —CH2O— or —S(O)n—(where n is 1);
Z2 is —O—, —OCH2— or —S(O)n—(where n is 1);
R1 and R4 are each independently hydrogen, halo, alkyl or —OR9;
R2is —C(NH)NH2, —C(NH)N(H)S(O)2R11 or —C(NH)N(H)C(O)N(H)R9;
R3 is ureido, guanidino, —N(R9)R10, —N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl) or (1,2)-imidazolinyl (optionally substituted by alkyl);
R5 and R6 are independently hydrogen, halo, alkyl or haloalkyl;
R7 is —X—CH2—[C(R13)H]p—C(R13)H2 where:
p is 0 to 5;
X is —O—, —S(O)n—(where n is 0 to 2), or —N(R9)—;
and each R13 is independently —[C(OR9)H]m—CH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); and
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl).

### Claim 4 (depends on 3)

The compound of claim 3 wherein:
A is —N=;
Z1 is —O—;
Z2 is —O—;
R1 is hydrogen or —OR9;
R2 is —C(NH)NH2;
R3 is (1,2)-tetrahydropyrimidinyl (optionally substituted by methyl), (1,2)-imidazolyl (optionally substituted by methyl) or (1,2)-imidazolinyl (optionally substituted by methyl);
R4 is hydrogen;
R5 and R6 are each halo;
R7 is —X—CH2—[C(R13)H]p—C(R13)H2 where:
p is 0 to 5;
X is —O—;
and each R13 is independently —[C(OR9)H]m—CH2—OR9 (where m is 1 to 4), [CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, [CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
each R9 and R10 is independently hydrogen or alkyl; and
each R11 is alkyl or aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl).

### Claim 5 (depends on 4)

The compound of claim 4 wherein:
A is —N=;
Z1 is —O—;
Z2 is —O—;
R1 is —OR9;
R2 is —C(NH)NH2;
R3 is (1,2)-imidazolyl (optionally substituted by methyl) or (1,2)-imidazolinyl (optionally substituted by methyl);
R4 is hydrogen;
R5 and R6 are both fluoro;
R7 is —X—CH2—[C(R13)H]pC(R13)H2 where:
p is 0 to 5;
X is —O—;
and each R13 is independently —[C(OR9)H]m—CH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9 or —[CH2]n—N(R9)R10 (where each n is independently 0 to 2); and
each R9 and R10 is independently hydrogen or alkyl.

### Claim 6 (depends on 5)

The compound of claim 5 wherein:
R7 is —O—CH2—C(OH)H—C(OH)H2.

### Claim 7 (depends on 6)

The compound of claim 6, namely, 3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2,3-dihydroxypropoxy)pyridin-2-yl]oxy]-4-hydroxybenzamidine.

### Claim 8 (depends on 2)

The compound of claim 2 wherein:
A is —N=;
Z1 is —O—, —CH2O or —S(O)n, (where n is 0 to 2);
Z2 is —O—, —OCH2— or —S(O)n—(where n is 0 to 2);
R1 and R4 are each independently hydrogen, halo or —OR9;
R2 is —C(NH)NH2, —C(NH)N(H)S(O)2R11 or —C(NH)N(H)C(O)N(H)R9;
R3 is ureido, guanidino, —N(R9)R10, —N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl);
R5 and R6 are independently hydrogen, halo, alkyl or haloalkyl;
R7 is selected from the group consisting of the following formulae: 20
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently —[C(OR9)H]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —(CH2)n—OC(O)R9, —[CH2]n—SC(O)R9, —(CH2]n—N(R9)C(O)R9, —[CH2]nOC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R14 is —X—[CH2]r— or —X—CH2—[C(R13)H]r—, where:
each r is independently 0 to 5, and
each X is —O—, —S(O)n—(where n is 0 to 2), or —N(R9)—; and
each R13 is independently —[CH(OR9)]mCH2—OR9 (where m is I to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]nN(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R11, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl).

### Claim 9 (depends on 8)

The compound of claim 8 wherein:
A is —N=;
Z1 is —O—;
Z2 is —O—;
R1 is hydrogen or —OR9;
R2 is —C(NH)NH2;
R3 is (1,2)-tetrahydropyrimidinyl (optionally substituted by methyl), (1,2)-imidazolyl (optionally substituted by methyl), or (1,2)-imidazolinyl (optionally substituted by methyl);
R4 is hydrogen;
R5 and R6 are each halo;
R7 is selected from the group consisting of the following formulae: 21
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently —[C(OR9)H]m—CH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —(CH2)n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R14 is —X—[CH2]r— or —X—CH2—[C(R13)H]r—, where:
each r is independently 0 to 5, and
each X is —O—, —S(O)n— (where n is 0 to 2), or —N(R9)—; and
each R13 is independently —[CH(OR9)]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
each R9 and R10 is independently hydrogen or alkyl; and
each R11 is independently alkyl or aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl).

### Claim 10 (depends on 9)

The compound of claim 9 wherein:
A is —N=;
Z1 is —O—;
Z2 is —O—;
R1 is —OR9;
R2 is —C(NH)NH2;
R3 is (1,2)-imidazolyl (optionally substituted by methyl), or (1,2)-imidazolinyl (optionally substituted by methyl);
R4 is hydrogen;
R5 and R6 are both fluoro;
R7 is selected from the group consisting of the following formulae: 22
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently —[C(OR9)H]m—CH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]nSR9 or —[CH2]n—N(R9)R10 (where each n is independently 0 to 2); and
each R14 is —X—[CH2]r— or —X—CH2—[C(R13)H]r—, where:
each r is independently 0 to 5, and
each X is independently —O—, —S(O)n—(where n is 0 to 2), or —N(R9); and
each R13 is independently [CH(OR9)]m—CH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]nSR9 or —[CH2]n—N(R9)R10; and
each R9 and R10 is independently hydrogen or alkyl.

### Claim 11 (depends on 10)

The compound of claim 10 wherein R7 is: 23
where
q is 0to 4;
each R13 is independently —[C(OR9)H]m—CH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9 or —[CH2]n—N(R9)R10 (where each n is independently 0 to 2); and
each R14 is —X—[CH2]r— or —X—CH2—[C(R13)H]r—, where:
each r is independently 0 to 5, and
each X is independently —O—, —S(O)n—(where n is 0 to 2), or —N(R9); and
each R13 is independently —[CH(OR9)]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9 or —[CH2]n—N(R9)R10; and
each R9 and R10 is independently hydrogen or alkyl.

### Claim 12 (depends on 11)

The compound of claim 11 wherein R7 is: 24
where
is 0 to 4;
each R13 is independently —[C(OR9)H]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]nSR9 or —[CH2]n—N(R9)R10 (where each n is independently 0 to 2); and
each R14 is —X—[CH2]r— where:
r is 0 to 5, and
X is —O—, —S(O)n—(where n is 0 to 2), or —N(R9); and
each R9 and R10 is independently hydrogen or alkyl.

### Claim 13 (depends on 12)

The compound of claim 12 wherein R7 is: 25
where
q is0to4;
each R13 is independently —[C(OR9)H]mCH2—OR9 (where m is 1 to 4), [CH2]nOR9 or —[CH2]nN(R9)R10 (where each n is independently 0 to 2); and
each R14 is —X—[CH2]r— where:
r is 0 or 1, and
X is —O—, and
each R9 and R10 is independently hydrogen or alkyl.

### Claim 14 (depends on 13)

The compound of claim 13 wherein R7 is: 26
where R14 is —O—; q is 3 and one R13 is in the 4-position of the tetrahydrofuranyl ring and is hydroxy, the second R13 is in the 2-position of the tetrahydrofuranyl ring and is 2,3-dihydroxyethyl and the third R13 is in the 5-position of the tetrahydrofuranyl ring and is ethoxy.

### Claim 15 (depends on 14)

The compound of claim 14, namely, 3-[[3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-[[2-(1,2-dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl]oxy]pyridin-2-yl]oxy]-4-hydroxybenzamidine.

### Claim 16

A pharmaceutical composition useful in treating a human having a disease-state characterized by thrombotic activity, which composition comprises a therapeutically effective amount of a compound selected from the group consisting of the following formulae: 27
wherein:
A is —C(R8)=or N=(where R8 is hydrogen, alkyl or halo);
Z1 is —O—, —N(R9), —CH2O— or —S(O)n— (where n is 0 to 2);
Z2 is —O—, —N(R9)—, —OCH2— or —S(O)n (where n is 0 to 2);
R1 and R4 are each independently hydrogen, halo, alkyl, nitro, —OR9, —C(O)OR9, —C(O)N(R9)R10, —N(R9)R10, —N(R9)C(O)R9, or —N(H)S(O)2R11;
R2 is —C(NH)NH2, —C(NH)N(H)OR9, —C(NH)N(H)C(O)OR11, —C(NH)N(H)C(O)R9, —C(NH)N(H)S(O)2R11, or —C(NH)N(H)C(O)N(H)R9;
R3 is hydrogen, halo, alkyl, haloalkyl, nitro, ureido, guanidino, —OR9, —C(NH)NH2, —C(NH)N(H)OR9, —C(O)N(R9)R10, —R12—C(O)N(R9)R10, —CH(OH)C(O)N(R9)R10, —N(R9)R10, —R12—N(R9)R10, —C(O)OR9, —R12—C(O)OR9, —N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl);
R6 and R6 are independently hydrogen, halo, alkyl, haloalkyl, nitro, —N(R9)R10, —C(O)OR9, —C(O)N(R9)R10, —C(O)N(R9)CH2C(O)N(R9)R10, —N(R9)C(O)N(R9)R10, —N(R9)C(O)R10, —N(R9)S(O)2R11, or —N(R9)C(O)N(R9)—CH2C(O)N(R9)R10;
R7 is —X—CH2—[C(R13)H]p—C(R13)H2 or —X—C([C(R13)H]p—C(R13)H2)2H where:
p is 0 to 5;
X is —O—, —S(O)n—(where n is 0 to 2), or —N(R9)—;
and each R13 is independently —[C(OR9)H]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]nN(R9)C(O)OR11, —[CH2]nOC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
or R7 is selected from the group consisting of the following formulae:
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently —[C(OR9)H]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]nN(R9)R10, —(CH2)n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]nOC(O)OR11, —[CH2]nN(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R14 is —X—[CH2]r— or —X—CH2—[C(R13)H]r—, where:
each r is independently 0 to 5, and
each X is —O—, —S(O)n—(where n is 0 to 2), or —N(R9)—; and
each R13 is independently —[CH(OR9)]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); and
each R12 is independently an alkylene or alkylidene chain;
as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable excipient.

### Claim 17

A method of treating a human having a disease-state characterized by thrombotic acitivity, which method comprises administering to a human in need thereof a therapeutically effective amount of a compound selected from the groupo consisting of the following formulae: 28
wherein:
A is —C(R8)=or N=(where R8 is hydrogen, alkyl or halo);
Z1 is —O—, —N(R9)—, —CH2O— or —S(O)n— (where n is 0 to 2);
Z2 is —O—, —N(R9), —OCH2— or —S(O)n— (where n is 0 to 2);
R1 and R4 are each independently hydrogen, halo, alkyl, nitro, —OR9, —C(O)OR9, —C(O)N(R9)R10, —N(R9)R10, —N(R9)C(O)R9, or —N(H)S(O)2R11;
R2 is —C(NH)NH2, —C(NH)N(H)OR9, —C(NH)N(H)C(O)OR11, —C(NH)N(H)C(O)R9, —C(NH)N(H)S(O)2R11, or —C(NH)N(H)C(O)N(H)R9;
R3 is hydrogen, halo, alkyl, haloalkyl, nitro, ureido, guanidino, —OR9, —C(NH)NH2, —C(NH)N(H)OR9, —C(O)N(R9)R10, —R12—C(O)N(R9)R10, —CH(OH)C(O)N(R9)R10, —N(R9)R10, —R12—N(R9)R10, —C(O)OR9, —R12C(O)OR9, —N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl);
R5 and R6 are independently hydrogen, halo, alkyl, haloalkyl, nitro, —N(R9)R10, —C(O)OR9, —C(O)N(R9)R10, —C(O)N(R9)CH2C(O)N(R9)R10, —N(R9)C(O)N(R9)R10, —N(R9)C(O)R10, —N(R9)S(O)2R11, or —N(R9)C(O)N(R9)—CH2C(O)N(R9)R10;
R7 is —X—CH2—[C(R13)H]p—C(R13)H2 or —X—C([C(R13)H]pC(R13)H2)2H where:
p is 0 to 5;
X is —O—, —S(O)n—(where n is 0 to 2), or —N(R9)—;
and each R13 is independently —[C(OR9)H]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]nN(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
or R7 is selected from the group consisting of the following formulae: 29
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently —[C(OR9)H]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]n—SR9, —[CH2]n—N(R9)R10, —(CH2)n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]n—N(R9)C(O)R9, —[CH2]n—OC(O)OR11, —[CH2]nN(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R14 is —X—[CH2]r— or —X—CH2—[C(R13)H]r—, where:
each r is independently 0 to 5, and
each X is —O—, —S(O)n— (where n is 0 to 2), or —N(R9)—; and
each R13 is independently —[CH(OR9)]mCH2—OR9 (where m is 1 to 4), —[CH2]n—OR9, —[CH2]nSR9, —[CH2]n—N(R9)R10, —[CH2]n—OC(O)R9, —[CH2]n—SC(O)R9, —[CH2]nN(R9)C(O)R9, —[CH2]nOC(O)OR11, —[CH2]n—N(R9)C(O)OR11, —[CH2]n—OC(O)N(R9)R10, or —[CH2]n—N(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); and
each R12 is independently an alkylene or alkylidene chain;
as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.
